UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported):
July 27, 2020
Phibro Animal Health Corporation
___________________________
(EXACT NAME OF REGISTRANT AS SPECIFIED IN
CHARTER)
|
Delaware |
|
01-36410 |
|
13-1840497 |
| (State or other jurisdiction of incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
Glenpointe Centre East, 3rd Floor
300 Frank W. Burr Boulevard, Suite 21
Teaneck, New Jersey 07666-6712
_______________________________________
(Address of Principal Executive Offices,
including Zip Code)
(201) 329-7300
__________________________________
(Registrant’s telephone number,
including area code)
Not Applicable
__________________________________
(Former name or former address, if changed
since last report)
Securities registered pursuant to Section
12(b) of the Act:
| Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
| Class A Common Stock, $0.0001 par value per share |
PAHC |
NASDAQ Stock Market |
Check the appropriate box below if this
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the
registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2
of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ¨
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
ITEM 8.01 OTHER EVENTS
On July 27, 2020, Phibro Animal Health Corporation
issued a press release announcing the declaration of a quarterly cash dividend of $0.12 per share on its Class A common stock and
Class B common stock, payable on September 23, 2020, to stockholders of record at the close of business on September 2, 2020. A
copy of the press release announcing the dividend is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated
herein by reference.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.
(d) Exhibits
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.
| |
PHIBRO ANIMAL HEALTH CORPORATION
Registrant |
| |
|
| Date: July 27, 2020 |
|
| |
|
| |
By: |
/s/ Thomas G. Dagger |
| |
Name:
Title: |
Thomas G. Dagger
Senior Vice President, General Counsel
and Corporate Secretary |
